Scientists reported today the first human recipients of laboratory-grown vaginal organs.
A research team led by Anthony Atala, M.D., director of Wake Forest Baptist Medical Center’s Institute for Regenerative Medicine, describes in the Lancet long-term success in four teenage girls who received vaginal organs that were engineered with their own cells.
“This pilot study is the first to demonstrate that vaginal organs can be constructed in the lab and used successfully in humans,” said Atala. “This may represent a new option for patients who require vaginal reconstructive surgeries. In addition, this study is one more example of how regenerative medicine strategies can be applied to a variety of tissues and organs.”
The girls in the study were born with Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, a rare genetic condition in which the vagina and uterus are underdeveloped or absent. The treatment could also potentially be applied to patients with vaginal cancer or injuries, according to the researchers.
The girls were between 13 and 18 years old at the time of the surgeries, which were performed between June 2005 and October 2008. Data from annual follow-up visits show that even up to eight years after the surgeries, the organs had normal function.
“Tissue biopsies, MRI scans and internal exams using magnification all showed that the engineered vaginas were similar in makeup and function to native tissue, said Atlantida-Raya Rivera, lead author and director of the HIMFG Tissue Engineering Laboratory at the Metropolitan Autonomous University in Mexico City, where the surgeries were performed.
In addition, the patients’ responses to a Female Sexual Function Index questionnaire showed they had normal sexual function after the treatment, including desire and pain-free intercourse.
The organ structures were engineered using muscle and epithelial cells (the cells that line the body’s cavities) from a small biopsy of each patient’s external genitals. In a Good Manufacturing Practices facility, the cells were extracted from the tissues, expanded and then placed on a biodegradable material that was hand-sewn into a vagina-like shape. These scaffolds were tailor-made to fit each patient.
About five to six weeks after the biopsy, surgeons created a canal in the patient’s pelvis and sutured the scaffold to reproductive structures. Previous laboratory and clinical research in Atala’s lab has shown that once cell-seeded scaffolds are implanted in the body, nerves and blood vessels form and the cells expand and form tissue. At the same time the scaffolding material is being absorbed by the body, the cells lay down materials to form a permanent support structure – gradually replacing the engineered scaffold with a new organ.
Followup testing on the lab-engineered vaginas showed the margin between native tissue and the engineered segments was indistinguishable and that the scaffold had developed into tri-layer vaginal tissue.
Current treatments for MRHK syndrome include dilation of existing tissue or reconstructive surgery to create new vaginal tissue. A variety of materials can be used to surgically construct a new vagina – from skin grafts to tissue that lines the abdominal cavity. However, these substitutes often lack a normal muscle layer and some patients can develop a narrowing or contracting of the vagina.
The researchers say that with conventional treatments, the overall complication rate is as high as 75 percent in pediatric patients, with the need for vaginal dilation due to narrowing being the most common complication.
Before beginning the pilot clinical study, Atala’s team evaluated lab-built vaginas in mice and rabbits beginning in the early 1990s. In these studies, scientists discovered the importance of using cells on the scaffolds. Atala’s team used a similar approach to engineer replacement bladders that were implanted in nine children beginning in 1998, becoming the first in the world to implant laboratory-grown organs in humans. The team has also successfully implanted lab-engineered urine tubes (urethras) into young boys.
The team said the current study is limited because of its size, and that it will be important to gain further clinical experience with the technique and to compare it with established surgical procedures.
The Latest on: Regenerative medicine
via Google News
The Latest on: Regenerative medicine
- BRIEF-China Regenerative Medicine International Proposes To Raise Between About Hk$351.72 Mln & Hk$354.23 Mlnon November 28, 2019 at 4:02 pm
Nov 28 (Reuters) - China Regenerative Medicine International Ltd: * PROPOSES TO RAISE NOT LESS THAN HK$351.72 MILLION & NOT MORE THAN ABOUT HK$354.23 MILLION BY ISSUING OFFER SHARES * TO ISSUE BETWEEN ...
- Regenerative Medicine Market: Facts, Figures and Analytical Insights 2019-2024on November 28, 2019 at 1:48 am
Nov 28, 2019 (AmericaNewsHour) -- As stated by the research report published by Azoth Analytics in August 2019, the Global Regenerative Medicine Market was valued at USD 22,814.45 million the year ...
- Hitachi develops automation technology of 3D culture to expand regenerative medicine businesson November 27, 2019 at 9:29 pm
Furthermore the support service to establish an automatic manufacturing process for customers who are considering automation of manufacturing regenerative medicine products will be started on December ...
- Global Regenerative Medicine Market Analysis 2018-2019 with Forecasts to 2025 - ResearchAndMarkets.comon November 27, 2019 at 4:30 pm
The "Regenerative Medicine Market Size, Outlook and Growth Opportunities, 2019- 2025" report has been added to ResearchAndMarkets.com's offering. This report includes the latest predictions of the ...
- Hitachi Developed Automation Technology of 3D Culture to Expand Regenerative Medicine Businesson November 26, 2019 at 8:17 pm
A schematic diagram of automated new 3D culture*10 Furthermore the support service to establish an automatic manufacturing process for customers who are considering automation of manufacturing ...
- Regenerative Medicine Firm Advances Multifaceted Pipelineon November 26, 2019 at 5:11 pm
RepliCel Life Sciences Inc. (RP:TSX.V; REPCF:OTCQB) announced in a news release the status of its various programs. Regarding its RCI-02 dermal injector, the biotech received the functional prototype ...
- AVITA Medical and Gates Center for Regenerative Medicine at CU Anschutz to collaborateon November 25, 2019 at 1:08 pm
Valencia, Calif., USA, Melbourne, Australia, and Aurora, Colo., USA, 24 November 2019 -- AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned ...
- AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz ...on November 24, 2019 at 2:45 pm
AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, and scientists at the ...
- Regenerative Medicine Market to Register Substantial Expansion by 2024on November 22, 2019 at 2:07 pm
Nov 22, 2019 (AB Digital via COMTEX) -- The growth in Regenerative Medicine Market is driven primarily by the rising prevalence of chronic diseases and genetic disorders and increasing government ...
- Heartseed Raises $26M in Series B Funding to Accelerate Development of iPSC-derived Regenerative Medicine for Heart Failureon November 22, 2019 at 4:00 am
which has supported Heartseed from Series A. “I have been involved in the research of cardiac regenerative medicine for the past 20-years as a pioneer in this field and solved all the major challenges ...
via Bing News